CAJ | 학술논문

背景:注射用重组人甲状旁腺素可以显著增加骨质形成、骨质密度,并显著减少骨折发生率,在治疗绝经后骨质疏松症方面具有良好的疗效. 目的:观察伊班膦酸钠联合重组人甲状旁腺素(1-34)治疗卵巢切除大鼠骨质疏松症的效果. 方法:32只健康大鼠随机数字表法均分成对照组、模型组、伊班膦酸钠组和伊班膦酸钠+甲状旁腺素组,除对照组外其他3组均进行卵巢切除,4周后分别皮下注射生理盐水或伊班膦酸钠或伊班膦酸钠+甲状旁腺素. 结果与结论:模型组大鼠骨钙含量明显低于其他3组,伊班膦酸钠+甲状旁腺素治疗可提高大鼠骨钙含量和骨密度,降低血钙和碱性磷酸酶水平,联合用药的作用优于单独用药.说明伊班膦酸钠对卵巢切除骨质疏松模型大鼠骨量的丢失有显著抑制作用,伊班膦酸钠联合甲状旁腺素可以增加骨含量,为治疗妇女绝经后骨质疏松提供了合理用药依据.
배경:주사용중조인갑상방선소가이현저증가골질형성、골질밀도,병현저감소골절발생솔,재치료절경후골질소송증방면구유량호적료효. 목적:관찰이반련산납연합중조인갑상방선소(1-34)치료란소절제대서골질소송증적효과. 방법:32지건강대서수궤수자표법균분성대조조、모형조、이반련산납조화이반련산납+갑상방선소조,제대조조외기타3조균진행란소절제,4주후분별피하주사생리염수혹이반련산납혹이반련산납+갑상방선소. 결과여결론:모형조대서골개함량명현저우기타3조,이반련산납+갑상방선소치료가제고대서골개함량화골밀도,강저혈개화감성린산매수평,연합용약적작용우우단독용약.설명이반련산납대란소절제골질소송모형대서골량적주실유현저억제작용,이반련산납연합갑상방선소가이증가골함량,위치료부녀절경후골질소송제공료합리용약의거.
BACKGROUND:Human recombinated parathyroid hormone can significantly improve the bone formation, increase the bone mineral density and reduce the rate of bone fracture. It is receipted that parathyroid hormone plays an important role in curing postmenopausal osteoporosis. @@@@OBJECTIVE:To investigate the efficacy of the combination therapy of human parathyroid hormone (PTH 1-34) and ibandronate in the treatment of ovariectomized rat osteoporosis. @@@@METHODS:Thirty-two health rats were randomly divided into control group, model group, ibandronate group and ibandronate+parathyroid hormone group. Except for the control group, the rats in the other three groups received ovariectomy. At 4 weeks after surgery, normal saline, ibandronate and ibandronate+parathyroid hormone were injected subcutaneously in the latter three groups, respectively. @@@@RESULTS AND CONCLUSION:The bone calcium content of the model rat group was significantly lower than of the other three groups, ibandronate+parathyroid hormone could improve the rat bone calcium content and bone mineral density and reduce the serum calcium and alkaline phosphatase levels, combination therapy was superior to monotherapy. In conclusion, ibandronate has a significant inhibitory effect on bone mass loss in ovariectomized osteoporosis rats. The combined use of ibandronate and parathyroid hormone can increase bone mineral content which provide the basis for the treatment of postmenopausal osteoporosis.